Therapeutic Response

CD30 + status confers therapeutic sensitivity to Brentuximab vedotin in combination with Dacarbazine, Doxorubicin, and Vinblastine in patients with Hodgkin Lymphoma.

Statements

Source and description
Adcetris (brentuximab vedotin) [product information]. EMA. The European Medicines Agency (EMA) has authorized brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine for the treatment of adult patients with previously untreated CD30+ stage III or IV Hodgkin lymphoma (HL).